Full-Life Technologies Reports First-in-Human Imaging Data for c-MET-Targeting Theranostic Ligand FL-261 Showing Robust Tumor Uptake, High Lesion Contrast and No Tracer-Related Serious Adverse Events in Patients with NSCLC

First-in-human imaging in 10 patients with non-small cell lung cancer showed no tracer-related serious adverse events, alongside high lesion contrast and tumor uptake. The data were featured as a Top Rated Oral Presentation at the 39th Annual Congress of the European Association of Nuclear Medicine; the small early-stage study does not establish broader clinical efficacy.